AURO-QUINAPRIL HCTZ TABLET

البلد: كندا

اللغة: الإنجليزية

المصدر: Health Canada

العنصر النشط:

QUINAPRIL (QUINAPRIL HYDROCHLORIDE); HYDROCHLOROTHIAZIDE

متاح من:

AURO PHARMA INC

ATC رمز:

C09BA06

INN (الاسم الدولي):

QUINAPRIL AND DIURETICS

جرعة:

20MG; 25MG

الشكل الصيدلاني:

TABLET

تركيب:

QUINAPRIL (QUINAPRIL HYDROCHLORIDE) 20MG; HYDROCHLOROTHIAZIDE 25MG

طريقة التعاطي:

ORAL

الوحدات في الحزمة:

2X14/90

نوع الوصفة الطبية :

Prescription

المجال العلاجي:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

ملخص المنتج:

Active ingredient group (AIG) number: 0231789003; AHFS:

الوضع إذن:

APPROVED

تاريخ الترخيص:

2019-01-02

خصائص المنتج

_AURO-QUINAPRIL HCTZ PRODUCT MONOGRAPH _
Page 1 of 56
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
AURO-QUINAPRIL HCTZ
Quinapril and Hydrochlorothiazide Tablets,
Tablets, 10 mg /12.5 mg, 20 mg /12.5 mg and 20 mg /25 mg Quinapril (as
Quinapril
Hydrochloride) / Hydrochlorothiazide, Oral
House Standard
Angiotensin Converting Enzyme Inhibitor/Diuretic
AURO PHARMA INC
3700 Steeles Avenue West, Suite # 402
Woodbridge, Ontario, L4L 8K8
Canada
Date of Initial Authorization:
January 02, 2019
Date of Revision:
August 11, 2023
Submission Control Number: 272657
_AURO-QUINAPRIL HCTZ PRODUCT MONOGRAPH _
Page 2 of 56
RECENT MAJOR LABEL CHANGES
N/A
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
..........................................................................................
2
TABLE OF CONTENTS
............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................... 4
1 INDICATIONS
.....................................................................................................................
4
1.1 Pediatrics (<18 years of age)
.......................................................................................
4
1.2 Geriatrics (> 65 years of age)
......................................................................................
4
2 CONTRAINDICATIONS
.......................................................................................................
4
3 SERIOUS WARNINGS AND PRECAUTIONS BOX
................................................................... 5
4 DOSAGE AND ADMINISTRATION
.......................................................................................
5
4.1 Dosing Considerations
.................................................................................................
5
4.2 Recommended Dose and Dosage Adjustment
...............